News | August 13, 2024
Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
Morepen Labs successfully raised Rs. 200 Crore through QIP
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Our centers are performing as expected or even better
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Expect the international business including CDMO business to pick-up in the second half of the financial year
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
Subscribe To Our Newsletter & Stay Updated
